In August 2024, Dr. Nagi El Saghir and colleagues published a key subgroup analysis from the RIGHT Choice Trial, comparing first-line ribociclib (RIB) plus endocrine therapy (ET) to combination chemotherapy (CT) in pre/perimenopausal patients with aggressive HR+/HER2– advanced breast cancer (ABC). The study confirmed that ribociclib + ET significantly prolonged progression-free survival with fewer severe side effects, reinforcing its role as a frontline option.
Dr. El Saghir’s expertise continues to shape breast cancer treatment, providing crucial insights into more effective and tolerable therapies for younger patients facing aggressive disease. His contributions to clinical research are invaluable in refining treatment strategies and improving patient outcomes.
Read the full study: https://lnkd.in/es3JmSx4
